AEGiS-14IAC: Prevalence and pattern of genotypic drug resistance among HIV Patients in Hong Kong.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Prevalence and pattern of genotypic drug resistance among HIV Patients in Hong Kong.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10185)

Yam WC, Wong KH, Lee SS
Queen Mary Hospital / The University of Hong Kong, Hong Kong, China

BACKGROUND: Presence of genotypic mutations that promote drug resistance has been associated with failure of anti-retroviral therapy. We examined the prevalence of mutations associated with resistance among patients enrolled in a clinical cohort in Hong Kong.

METHODS: Plasma of patients were collected for HIV genotyping analysis to identify resistance mutations in Protease and Reverse Transcriptase (RT) sequences using the ABI HIV-1 Genotyping System and Stanford database.

RESULTS: HIV viral Protease and Reverse Transcriptase (RT) sequences from 52 patients (17 naïve and 35 treatment failure) were characterized to 27 B subtype, 23 A/E subtype, 1 C subtype and 1 D subtype. The most prevalent protease mutations were M36I (74%), L63P (47%), I93L (34%), V77I (19%), and A71V (13%). The distribution of the resistance mutations was as follows: to NRTIs in 20/52; 10 to 3TC (M184V), 5 to DDI (L74V), 4 to ZDV (T215Y) and 1 to ZDV + 3TC (M184V + T215Y); to NNRTIs in 4/52; 4 â ù K103N, and to protease inhibitors in 11/52 (L90M, V82A, I84V). Resistance mutations to 2 classes of anti-retrovirals were present in 7/52 samples. A multi-drug resistance pattern was observed in 1 B subtype, conferring high level resistance to the 3 classes of anti-retrovirals including protease inhibitors (APV, IDV, NFV, RTV, and SQV), NRTIs (DDI, DDC, and ABC), and NNRTIs ( EFV, DLV, and NVP).

CONCLUSIONS: Genotyping of viral Protease and RT sequences should facilitate studies of HIV-1 drug resistance. Due to evolution in pattern of mutations, resistance testing shall be applied to guide the usage of anti-retroviral treatments. Larger studies and clinical correlates are needed before any conclusions can be drawn.

Keywords: AEGIS, Prevalence, HIV Infections, Zidovudine, HIV-1, Lamivudine, Drug Resistance, Viral, HIV Seropositivity, Didanosine, HIV Protease, RNA-Directed DNA Polymerase, Zalcitabine, HIV Protease Inhibitors, Drug Resistance, Genotype, Hong Kong, Human, genetics

020707
B10185

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.